Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor

Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor

The majority of gastrointestinal stromal tumor (GIST) patients develop resistance to the first-line KIT inhibitor, imatinib mesylate (IM), through acquisition of secondary mutations in KIT or bypass signaling pathway activation. In addition to KIT, AKT is a relevant target for inhibition, since the...

Full description

Bibliographic Details
Main Authors: Marya Kozinova, Shalina Joshi, Shuai Ye, Martin G. Belinsky, Dinara Sharipova, Jeffrey M. Farma, Sanjay S. Reddy, Samuel Litwin, Karthik Devarajan, Alex Rosa Campos, Yi Yu, Brian Schwartz, Margaret von Mehren, Lori Rink
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
gastrointestinal stromal tumor
GIST
AKT
PDCD4
imatinib mesylate
Online Access:https://www.mdpi.com/2072-6694/13/15/3699

Internet

https://www.mdpi.com/2072-6694/13/15/3699

Similar Items